{"name":"Pear Therapeutics","slug":"pear-tx","ticker":"PEAR","exchange":"NASDAQ (Delisted)","domain":"peartherapeutics.com","description":"Pear Therapeutics is a digital therapeutics company focused on developing prescription software to treat various mental health conditions. Their key products include Somryst for insomnia and reSET for substance use disorder. As a leader in the digital therapeutics market, Pear Therapeutics has established partnerships with major pharmaceutical companies and has received regulatory approvals for its products.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Corey McCann, M.D., Ph.D. (former)","sector":"Digital Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$0 (Bankrupt)","metrics":{"revenue":12694000,"revenueGrowth":201.7,"grossMargin":0,"rdSpend":48311000,"netIncome":-75491000,"cash":95129000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Pear Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Pear Therapeutics reported its fourth quarter and full year 2023 financial results, with revenue of $43.1 million and a net loss of $64.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Pear Therapeutics Announces Collaboration with Novartis to Develop Digital Therapeutics for Mental Health","summary":"Pear Therapeutics announced a collaboration with Novartis to develop digital therapeutics for mental health conditions, including depression and anxiety.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"regulatory","headline":"FDA Approves Pear Therapeutics' reSET-O for Opioid Use Disorder","summary":"The FDA approved Pear Therapeutics' reSET-O, a digital therapeutic for opioid use disorder, marking the company's second FDA-approved product.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQVnJab2xMSlRpcVQ0a1hZVS1NcTd4V0NYVVFqZ2xWbUhHdndqX3BTUmVpcHVsdGRXT3NPcWgwNVJtaGdYNjNab0VqcGdxTGNST3k0ZnRLaEpqRldUWWI2OVE2c1lVTG9FSGc5LXdIMU4wVWd2b2dGX1RabFNIS2s2VzBUMTVTOHVUSmdyS1ZsLTdkR29rU2RvTkR3?oc=5","date":"2024-08-22","type":"pipeline","source":"statnews.com","summary":"Digital therapeutics pioneer Pear’s treatments get a second life, a year after bankruptcy - statnews.com","headline":"Digital therapeutics pioneer Pear’s treatments get a second life, a year after bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1VTHZNX1IzSW9ZWHNVTmh3ZDdvaTdHVDh6Q0p0bnBOdnNyOVFreVJ2MUNxYVI5MU5ydWd4aE1vTDZ4S3NlZ3FxbnZGeVA2Um9kVTRfVTNsb1h4cnVsTjNucVFWRjhrWnM4djdva042LVFidENjYUE?oc=5","date":"2024-08-22","type":"pipeline","source":"pharmaphorum","summary":"The fall and rise of digital therapeutics - pharmaphorum","headline":"The fall and rise of digital therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOYWFXMzZiR20xZXFCUldiME5qcXNpeEItVkNYZ0djRDUtdU92VTliV2dRdmh3TTFmdnZBWTQ3bmlnQlFVZkFGaVhyclVuZnpkQTRrRFNMWXZUbnNubEFXRXktUzB4a2FRN0RBNXlncFV1WXdRRG4yWlI0Q1JaMWpmNDQ5MnVGYVNZcElaYWlobUhsNXJmd251UC1aS0dWTWNzb2F0RnhDZ1BWXzRsRUVUUg?oc=5","date":"2023-10-24","type":"pipeline","source":"Pharmaceutical Technology","summary":"Pear Therapeutics: a lesson for future DTx developers - Pharmaceutical Technology","headline":"Pear Therapeutics: a lesson for future DTx developers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQYzlmbmEyZnM0M2V4RDlLTURkeVVMTEoxbW1ISTVwX2pOSFJnQWxjTTBxXzRUN1dVSU02UnV4MHdyMjh6Y01ZV2hhT3BxRWs0eE1Yc01TRTFJRkppOERBbHpTOGRyM0thSmI0VnZBMkFwS25iTUtKdHhmemdqbWZDUmZLRWh3MFhiajlmY1B3bDJJVXd6NE5McTdqOGhnaFpNTU9N?oc=5","date":"2023-06-09","type":"pipeline","source":"Managed Healthcare Executive","summary":"What Does Pear Therapeutics’ Bankruptcy Mean for PDTs? - Managed Healthcare Executive","headline":"What Does Pear Therapeutics’ Bankruptcy Mean for PDTs?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOV1hBY043M28wTTNlU1ZGWVpWamhneWJPSGk0MHBhUVZXREZ1X2dwc2hUbkRRYUpRaDR0VDd0T09VZURVdFlYQXJtWWs2NW5GREdvelRBeDdqaGhfbkRaek43eWhNNUpSeE40bXFzdllkNXJsdFQ4OHVqV19EcDdZTDMxN0dIMFdXTEUwVHRwVUdfTjBkRW9aMzdZQzBSbVpMN2xlQWZ3cVFqZnNPOGVGMFZiTDFIYVNSMDk4bUw4OHRoQQ?oc=5","date":"2023-05-19","type":"pipeline","source":"Fierce Biotech","summary":"Pear pulped: Digital therapeutics maker's assets sold for $6M at auction after bankruptcy filing - Fierce Biotech","headline":"Pear pulped: Digital therapeutics maker's assets sold for $6M at auction after bankruptcy filing","sentiment":"neutral"},{"date":"2023-04-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPVEhrYVk2NXFBdV9NZzd4RmM0SFpCMGxVRjRWWEZ4M0xFY3MwLWIzUGlMUVFUWF84dm9RMnBjWGllUVptMnlaWDRYSTlXZ3hyblhrV0F4YlMwb3ZYeHVqYjk3NExtNlYzR1Q0TjU0YWpJMmdGckVUQnpua3k3WHdOd0hn?oc=5","date":"2023-04-07","type":"pipeline","source":"BioPharma Dive","summary":"Pear Therapeutics files for Chapter 11 bankruptcy - BioPharma Dive","headline":"Pear Therapeutics files for Chapter 11 bankruptcy","sentiment":"neutral"},{"date":"2023-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2023-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZm11dzR2aXVYMmF6LUtlYkVvb0ZPclpXalIzZ1llNmdZeWs2ZlBpcGdSOHY5RlVoNnZNM1k0a2J0M21CbGJvY3VKZkdaclpnbGEwYnRNRlRDYUctZUtSOHViNVJyZElnMWliMi05R05FdzBQM095RFN2VjdJeGVaVm1TYmFUaWhpbDhJQWRtVjF1R3RCeGYzWjllQjY0UGhFYnFOWg?oc=5","date":"2022-04-29","type":"pipeline","source":"HealthLeaders Media","summary":"Digital Therapeutics Companies Make the Case for Pharma's Support - HealthLeaders Media","headline":"Digital Therapeutics Companies Make the Case for Pharma's Support","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPTldiSEZXdVZTMFJwZnIxYXpUdEliLUxzYlVfUXltWTZpOUU4T3FXb3BqV1Z0eXNOdU41RGx3aVBUcnpTVVBlbWhWYVhBcWRNa0szX2RZcEE0VFN2UTJPOWQ2RmN1RGZpRFpJMndJRF95aVNuYlhEaDZ2eWhxYXFhQ1pORXp5UlBVMEt0cVc4U2NLck9MRkFBNU9DZHh2RnhheVBvdg?oc=5","date":"2021-01-14","type":"deal","source":"MedCity News","summary":"‘Smart pill’ startup etectRx strikes partnership with Pear Therapeutics - MedCity News","headline":"‘Smart pill’ startup etectRx strikes partnership with Pear Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQQXVXRUVVTUl1VkxiWlUtTWZOZ3NfTDZZaDBDdGJNTUV2YnMxRTAtWnlONnBiSW8tRVFPLVRuX09oVUJFM01xWGxSdjVVUFNxZWk3VjRHeWxfT0xLcV91N3E3bnFYU2tEODR4ZDdWU1VnckszOFc2dFUxbkhGRF9HdlRLZVd2aHZRSS1QV0pPaHBXY0NIWEtNbVZVV0ZoWEFtWElIY2JB?oc=5","date":"2020-01-22","type":"pipeline","source":"Business Insider","summary":"Pear Therapeutics CEO Corey McCann on Pharma's Digital Commitment - Business Insider","headline":"Pear Therapeutics CEO Corey McCann on Pharma's Digital Commitment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQQmxVWFNTRXNRTlNBT3ZjYmZOc1JhX2pEcnFmalRiMWxYX0RIVmpMMUJJU203OEd0SEw4dG55N2gzRnhPTXN6Uk5QZC1HcTkzNVhWVVZHOXlUMGpsQzR2YUVGZjZ4UVBXLU9ONU9FV2ZMT3kxdnFsbF85MjBDd1N1TXEtemkwb2hEdzZuSVVsNjZOYXU0YXhFLUhLN1pBVzlBLXdKRmZB?oc=5","date":"2019-10-16","type":"deal","source":"Fierce Biotech","summary":"Novartis' Sandoz drops out of prescription app deal with Pear Therapeutics - Fierce Biotech","headline":"Novartis' Sandoz drops out of prescription app deal with Pear Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Akili Interactive","Click Therapeutics","Orexo AB"],"therapeuticFocus":["Mental Health","Neurology"],"financials":{"source":"sec_edgar","revenue":12694000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":12694000,"period":"2022-12-31"},{"value":4208000,"period":"2021-12-31"},{"value":4208000,"period":"2021-12-31"},{"value":9384000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":48311000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-75491000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":95129000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}